Psoriasis Tied to Kidney Disease in T2D, Despite Treatment
METHODOLOGY:
Researchers conducted a retrospective cohort analysis using TriNetX data from 2014-2024, which included patients with T2D who started treatment with angiotensin-converting enzyme inhibitors (ACEis), angiotensin II receptor blockers (ARBs), or sodium-glucose cotransporter-2 inhibitors (SGLT2is).
After propensity score matching, 27,044 patients were included in two cohorts — with and without psoriasis, diagnosed before starting renoprotective therapy.
A total of 7771 patients with psoriasis received biologics, including interleukin (IL)-23, IL-17, IL-12/23, or tumor necrosis factor (TNF) alpha inhibitors.
Study outcomes were diabetic nephropathy, CKD, ESRD, and need for dialysis at 3, 5, and 10 years.
TAKEAWAY:
At 3 years, patients with psoriasis demonstrated a significantly higher risk for diabetic nephropathy (absolute risk increase [ARI], 1.31; P < .0001), CKD (ARI, 1.80; P < .0001), ESRD (ARI, 0.38; P < .0001), and dialysis (ARI, 0.28; P < .0001).
< .0001), CKD (ARI, 1.80; < .0001), ESRD (ARI, 0.38; < .0001), and dialysis (ARI, 0.28; < .0001). The increased risk persisted at 5 years (ARI, 2.02, 3.28, 0.58, 0.42, respectively; all P < .0001), and at 10 years (ARI, 3.30, 6.33, 0.94, 0.63, respectively; all P < .0001).
< .0001), and at 10 years (ARI, 3.30, 6.33, 0.94, 0.63, respectively; all < .0001). Patients with psoriasis who received biologics showed a higher risk for CKD at 10 years despite renoprotective therapy ( P < .0001) than those without psoriasis.
IN PRACTICE:
'Psoriasis may trigger a T-helper-17-driven inflammatory response, leading to the production of cytokines such as IL-17, IL-12/23, and TNF,' which induce renal inflammation, and this process is 'not targeted by ACEis, ARBs, or SGLT2is,' which may explain the persistently elevated CKD risk in patients with both T2DM and psoriasis, according to the study authors. They added that the findings support earlier evidence that 'biologics do not ameliorate the deterioration of renal function' in those with existing renal issues and a prospective study is needed to confirm these associations.
SOURCE:
The study was led by Tarun Sontam, Texas A&M School of Medicine, Dallas, Texas, and was published online on May 7 in the Journal of the American Academy of Dermatology .
LIMITATIONS:
The study did not account for psoriasis severity or duration and adherence to renoprotective therapy. The authors noted that uncontrolled factors might influence the findings.
DISCLOSURES:
The authors reported having no conflicts of interest. The study had no funding source.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
17 hours ago
- Business Wire
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
NEW YORK--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ('TNF' or the 'Company'), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025. 'The recent significant improvement in our financial position gives TNF a stronger platform for growth opportunities and taking advantage of shareholder value creation opportunities,' said TNF President and Chief Medical Officer, Mitchell Glass, M.D. 'We are pleased to have the continued support of our largest investors, and look forward to updating investors on TNF's business developments in the near future, including our ongoing collaboration with Renova on GLP-induced inflammation and muscle damage.' The improvements in the Company's financial position will be reflected in future financial statements of the Company. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'may,' 'plan,' 'will,' 'would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact our liabilities due to adverse market conditions, the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Medscape
2 days ago
- Medscape
Oral Minoxidil For Hair Loss Not Linked to Tachycardia
TOPLINE: In a large retrospective study of patients with androgenic alopecia or other nonscarring hair loss, treatment with low-dose oral minoxidil (LDOM) was not associated with an increased risk for tachycardia. METHODOLOGY: Researchers conducted a study of 524,522 patients with androgenic alopecia or other nonscarring hair loss, who did not have a history of hypertension, tachycardia, or arrhythmia (about 62% White; 9% Black; 10% Hispanic or Latino individuals) from the TriNetX database from 2004 to 2024. Of those patients, 9267 were on LDOM (≤ 5 mg/d minoxidil, used off-label for treating hair loss); the rest were minoxidil-naïve. In the LDOM vs control group, patients were older (mean age, 45.5 years vs 39.8 years; P < .0001) and there were more men (33% vs 19%, P < .0001). The study outcome was the risk for tachycardia. TAKEAWAY: A total of 126 patients (7.7%) who received LDOM were diagnosed with tachycardia; the median time to diagnosis was 245 days. The risk for tachycardia was not significantly different among patients treated with LDOM compared with controls (hazard ratio [HR], 0.90; CI, 0.76-1.08), and there was no association between LDOM and tachycardia (HR, 0.92; 95% CI, 0.77-1.10). The risk for tachycardia was lower in men than women (HR, 0.64; 95% CI, 0.62-0.67) and in Asian patients (HR, 0.81; 95% CI, 0.76-0.88). Black (HR, 1.19; 95% CI, 1.13-1.25) and White patients (HR, 1.29; 95% CI, 1.25-1.34) showed an increased risk for tachycardia. IN PRACTICE: The results suggest that 'hair loss treatment with LDOM is safe in patients without cardiac risk factors, and therefore, coadministration of beta-adrenergic blockers is not recommended,' the authors wrote, noting that large prospective studies are needed to confirm their findings. The study, they added, is the largest to date 'analyzing tachycardia risk with LDOM treatment for nonscarring hair loss and the only study with a control group.' SOURCE: The study was led by Zachary Neubauer, Thomas Jefferson University, Sidney Kimmel Medical College, Philadelphia, Pennsylvania, and was published online on August 8 in the Journal of the American Academy of Dermatology. LIMITATIONS: The retrospective design and reliance on diagnostic coding could have introduced bias. Dosing frequency and cardiac monitoring data were unavailable. Transient tachycardia episodes might have been missed, and physician prescribing behavior could have influenced patient selection. DISCLOSURES: The study did not receive any funding. One author disclosed receiving research funding from Moberg Pharmaceuticals and BelleTorus Corporation. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Newsweek
5 days ago
- Newsweek
Map Shows Where Power Outages Are Most Common in the US
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. From Winter Storm Blair to Hurricane Beryl in Texas and the more recent Connecticut thunderstorms, power outages from severe weather events have become an increasingly common reality across the United States in recent years. A nationwide study from the Urban Resilience AI Lab at Texas A&M University has produced the first-ever Power System Vulnerability Index (PSVI)—a classification of each county identifying those most at risk of frequent and prolonged blackouts. "Using data from Oak Ridge National Laboratory, we studied the effect of weather events on the frequency and duration of nationwide power outages over the past 10 years," explained paper author and civil engineer Junwei Ma in a statement. "The dataset included over 179 million data points sorted by time and location, allowing us to create the PSVI." Where US Power Outages Hit Hardest The researchers' analysis examined outages between 2014 and 2023 across 3,022 U.S. counties, covering 96 percent of the contiguous United States. Results showed a steady nationwide rise in power system vulnerability, with 318 counties across 45 states now considered "hotspots" for high risk. Regions Most Vulnerable to Blackouts According to the PSVI data, the most vulnerable U.S. regions include: The West Coast, particularly California and Washington The East Coast, including Florida and the Northeast megalopolis The Great Lakes corridor (Chicago–Detroit) Gulf Coast areas of Texas The average county experienced outages lasting 7.3 days per year—roughly 2 percent of the year without power—with an outage occurring about once a week. Since 2019, outage duration, frequency, and scale have increased by around 20 percent annually. Why Vulnerability Is Rising Researchers linked many spikes in vulnerability to extreme weather disasters such as wildfires in California, hurricanes in Florida, and the 2021 Texas winter storm. However, non-weather factors, including aging electrical grids, rising energy demand, and urban development density, also play a major role. Urban counties, with dense populations and infrastructure, showed significantly higher vulnerability than rural areas. "Dense street trees, heavy electricity demand, and concentrated infrastructure mean cities are hit harder and recover more slowly from outages," Ma explained. How the Power System Vulnerability Index Works The PSVI was built using explainable A.I., a machine learning method that weighs outage frequency, intensity, and duration to produce a county-by-county score. This publicly available tool allows users to explore vulnerability trends over the past decade and compare risks nationwide. "We're turning 179 million messy outage logs into a roadmap for prevention—showing each county whether its biggest pain point is too many outages, too long, or too large," paper author and civil engineer professor Ali Mostafavi told Newsweek. Why It Matters The team also warned that many A.I. data centers and critical facilities are located in high-risk zones, underscoring the need for targeted investment in resilient infrastructure as severe weather events are expected to become more frequent. "The data show a clear pattern: U.S. power outages are becoming more frequent, longer, and clustered in hotspot counties," Mostafavi said. "By turning high-frequency outage logs into a county-level Power-System Vulnerability Index, we see not only where the grid struggles, but why—whether the main issue is too many events, too many customers affected, or restorations that take too long. "Without targeted upgrades, today's chronic pockets will intensify during climate extremes." The index represents the first transparent, nationwide, county-level view of grid vulnerability built from high-frequency, utility-reported outages, Mostafavi continued. "It moves the conversation from anecdotes to comparable metrics every policymaker can understand." He concluded: "With climate extremes intensifying and electrification accelerating, leaders need clear, data-driven targets for hardening the grid and protecting residents." Do you have a tip on a science story that Newsweek should be covering? Do you have a question about power outages? Let us know via science@ Reference Ma, J., Li, B., Omitaomu, O. A., & Mostafavi, A. (2025). Establishing nationwide power system vulnerability index across US counties using interpretable machine learning. Applied Energy, 397.
